Last reviewed · How we verify
Spinal muscular atrophy with two copies of a healthy SMN2 gene
Approved treatments
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
- PF-06939999 dose escalation · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Spinal muscular atrophy with two copies of a healthy SMN2 gene patent landscape — cliff calendar, originator estates, attackable patents
- Spinal muscular atrophy with two copies of a healthy SMN2 gene treatment landscape brief
- Spinal muscular atrophy with two copies of a healthy SMN2 gene treatment updates RSS
Frequently asked questions about Spinal muscular atrophy with two copies of a healthy SMN2 gene
What drugs treat Spinal muscular atrophy with two copies of a healthy SMN2 gene?
Tracked treatments include PF-06939999 dose escalation.
What is the treatment for Spinal muscular atrophy with two copies of a healthy SMN2 gene?
Standard treatment for Spinal muscular atrophy with two copies of a healthy SMN2 gene includes PF-06939999 dose escalation. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Spinal muscular atrophy with two copies of a healthy SMN2 gene patent cliff · Spinal muscular atrophy with two copies of a healthy SMN2 gene CI report
- Treatment: PF-06939999 dose escalation · Pfizer
- Treatment: PF-06939999 dose escalation · Pfizer
- Treatment: PF-06939999 dose escalation · Pfizer
- Treatment: PF-06939999 dose escalation · Pfizer
- Treatment: PF-06939999 dose escalation · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing